Program
TAK-003
A development code. Also written as “TDV” and “Tetravalent Dengue Vaccine (TDV)”.
Its studies are mostly in Dengue, led by Takeda.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Takeda | 63 open or running | phase 3since Jan 31, 2018 | Jan 31, 2018 | Apr 14, 2027phase 3 · NCT06579755 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 31, 2018First study: phase 3 study in DengueFirst studyNCT03423173 · 923 enrolled · United States
- Sep 22, 2023Phase 3 study in Healthy VolunteersNCT06060067 · 480 enrolled · India
- Aug 29, 2024Phase 3 study in DengueNCT06579755 · 800 enrolled · Argentina, Brazil, Singapore and more
- Oct 29, 2024Phase 3 study in DengueNCT06665035 · 212 planned · Colombia, Thailand
- Dec 15, 2024Phase 3 study in DengueNCT06741683 · 187 enrolled · Japan
- Jun 24, 2025Phase 3 study in DengueNCT07047521 · 496 enrolled · Australia
Ahead
- Apr 14, 2027Primary completion: phase 3 study in DengueNCT06579755
- Mar 3, 2030Primary completion: phase 3 study in DengueNCT06665035
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07047521Dengue · Australia | 3 | Active, not recruiting | Jun 29, 2026 | 496 |
| NCT06741683Dengue · Japan | 3 | Completed | Jul 9, 2025 | 187 |
| NCT06665035Dengue · Colombia, Thailand | 3 | Recruiting | Mar 3, 2030 | 212 |
| NCT06579755Dengue · Argentina, Brazil, Singapore and more | 3 | Active, not recruiting | Apr 14, 2027 | 800 |
| NCT06060067Healthy Volunteers · India | 3 | Completed | May 5, 2025 | 480 |
| NCT03423173Dengue · United States | 3 | Completed | Aug 3, 2018 | 923 |
How it is read
Names in the registry
- “TDV”, 4 entries
- “Tetravalent Dengue Vaccine (TDV)”, 1 entry
- “TAK-003”, 1 entry
Codes read as this program: TAK003.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.